All In Biotech

Drug Trial Radar · NCT05795816

Effectiveness of Testofen Compared to Placebo on Long COVID Symptoms

The Effectiveness of Testofen on Energy, Fatigue, Mental Acuity, and Other Quality of Life Symptoms Post COVID-19 Infection

Last checked: Nov 19, 2026Latest source record: Mar 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

150

Actual

Start

Oct 25, 2023

Primary completion

Jan 30, 2025

Study completion Jan 31, 2025

Sponsor

Lead sponsor
RDC Clinical Pty LtdIndustry
Sponsor type
Industry
First posted
Apr 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a double blind, randomised, placebo-controlled trial to evaluate orally-dosed Testofen (a specialised extract of Trigonella foenum-graecum (Fenugreek) seed) compared to placebo on post COVID-19 symptoms in otherwise healthy participants 18 years and over.

Conditions

  • Long Covid19

Interventions

  • TestofenDrug

    Twice daily dose of 1 capsule (300mg per capsule Testofen)

  • Microcrystalline celluloseDrug

    Twice daily dose of 1 capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Energy and FatigueTime frame: Baseline, week 4, week 8 and week 12
  2. Change in Energy and FatigueTime frame: Baseline, week 4, week 8 and week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • RDC Clinical Pty Ltd

    Brisbane, Queensland, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.